Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab
Asia-Pacific Journal of Clinical Oncology · 2024
DOI: 10.1111/ajco.13940 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Asia-Pacific Journal of Clinical Oncology, 2024. Verfasst von Udit Nindra und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 16 Literaturangaben.
Abstract (Originalsprache)
Background
Consolidation durvalumab after concurrent chemoradiation is the standard of care for unresectable stage III non‐small cell lung cancer (NSCLC) based on the PACIFIC trial. However, there have been reports in the literature suggesting the efficacy of the treatment differs in patients whose tumors harbor epidermal growth factor receptor ( EGFR ) mutations and in those with low programed death ligand‐1 (PD‐L1) expression. This study describes the survival outcomes for patients with unresectable stage III NSCLC treated with chemoradiation followed by durvalumab with a specific focus on EGFR mutation status and PD‐L1 expression.
Methods
This retrospective observational study was conducted across six sites in Greater Sydney, Australia. It included all patients diagnosed with unresectable stage III NSCLC treated with chemoradiation and who received at least one cycle of durvalumab between January 2018 and September 2021. Patients were stratified according to EGFR mutation status and PD‐L1 tumor proportion score (TPS) of 1%.
Results
Of the 145 patients included in the analysis, 15/145 (10%) patients harbored an EGFR mutation and 61/145 (42%) patients had PD‐L1 TPS of
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Liverpool Hospital, Liverpool, Australia.
- Department of Medical Oncology, Westmead Hospital, Sydney, Australia.
- Department of Medical Oncology, Chris O'Brien Lifehouse, Sydney, Australia.
- Department of Clinical Medicine, Macquarie University, Sydney, Australia.
- Department of Medical Oncology, Macarthur Cancer Therapy Centre, Campbelltown Hospital, Campbelltown, Australia.
- School of Medicine, Western Sydney University, Sydney, Australia.
Zitieren
APA
Nindra, U., Shahnam, A., Stevens, S., Pal, A., Nagrial, A., Lee, J., Yip, P. Y., Adam, T., Boyer, M., Kao, S., & Bray, V. (2024). Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. https://doi.org/10.1111/ajco.13940
Vancouver
Nindra U, Shahnam A, Stevens S, Pal A, Nagrial A, Lee J, et al. Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab. Asia-Pacific Journal of Clinical Oncology. 2024. doi:10.1111/ajco.13940
BibTeX
@article{Nindra2024,
author = {Nindra, Udit and Shahnam, Adel and Stevens, Samuel and Pal, Abhijit and Nagrial, Adnan and Lee, Jenny and Yip, Po Yee and Adam, Tamiem and Boyer, Michael and Kao, Steven and Bray, Victoria},
title = {Influence of EGFR mutation status and PD‐L1 expression in stage III unresectable non‐small cell lung cancer treated with chemoradiation and consolidation durvalumab},
journal = {Asia-Pacific Journal of Clinical Oncology},
year = {2024},
doi = {10.1111/ajco.13940}
}
EUVIMED